Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia
This study has been completed.
Study NCT00313053   Information provided by Stanford University

First Received on April 7, 2006.   Last Updated on May 31, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia, Lymphocytic, Acute
Leukemia
Acute Lymphoid Leukemia (ALL)
Additional conditions recognized in this trial
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Human mAb 216
Vincristine
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Stanford University
National Institutes of Health (NIH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services